Search

everythinglearnresearchcommunity

for

Search:↓

A 19-year-old started treating male pattern baldness with topical minoxidil, finasteride tablets, microneedling, and is considering PRP injections. They are concerned about the effectiveness and timing of these treatments.

PP405 is being discussed as a potential new approach to hair loss by targeting follicle stem cells, suggesting a different mechanism from existing treatments like finasteride and minoxidil. However, there is skepticism about whether it will lead to meaningful long-term outcomes or follow the pattern of previous treatments that showed promise but lacked consistent results.

An 18-year-old is using finasteride for hair loss prevention despite having a healthy hairline. Opinions are mixed, with some advising against its use at his age and others supporting his proactive approach.

PP405 is a potential new hair loss treatment that might replace finasteride and minoxidil, but it is still in clinical trials and may not be available until 2028-2031. There is skepticism about its effectiveness, with only a 20% increase in hair density observed in some participants.

A 21 year old who has been taking various treatments for hair loss such as dutasteride, RU58841, minoxidil and finasteride with no results. Other users share their experiences of dealing with hair loss at an early age and offer advice on how to cope.

A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

PP405 is a medicine, and Google Ventures is funding its development based on evidence from each phase, unlike their investment in Juicero, which was a trend-based gamble. Investing in medicine is a calculated risk, not reliant on being "cool."

The user is concerned about mixing Pantostin (with Alfatradiol) and Finasteride in a topical solution, fearing a potential toxic reaction or ineffectiveness. They seek advice on whether this combination is safe.

The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.

The user is concerned about using dutasteride for potential hair loss, fearing it might accelerate balding if not effective. They are unsure about the doctor's diagnosis and are considering starting with finasteride instead.

The user is experiencing a lack of morning erections after using 0.5mg of finasteride every other day for two weeks and is considering whether to reduce the dose, continue, or stop. The discussion focuses on adjusting finasteride dosage due to side effects.

A 22-year-old is using 1mg finasteride daily for hair loss, noting some scalp thickening but still experiencing visible thinning. They are considering oral minoxidil due to concerns about topical application with cats at home, and others in the conversation share positive experiences with oral minoxidil, reporting no side effects and significant hair regrowth.

Everychem's solution, similar to PP405, has mixed results for hair regrowth, with some users reporting improvements and others seeing no change or worsening hair loss. Users are sharing experiences and updates to determine its effectiveness.

A 20-year-old has been using finasteride for 2 years and switched from 5% to 10% minoxidil, causing issues. The doctor now prescribes 5% minoxidil twice daily, dutasteride on alternate days, and 3 PRP sessions for hair regrowth.

A user is making their own dutasteride solution using MCT oil but is concerned about its effectiveness and bioavailability. They are considering using propylene glycol or adding ethanol for better results, while others suggest the current dosage might be excessive.

A user is considering making a 2% clascoterone lotion from powder due to unavailability in their location. They plan to mix clascoterone powder with retinol lotion and use literature to determine the correct dosage.

Dr. Gabel doesn't use Verteporfin because it's not FDA approved. The user is getting FUT and wants to minimize scarring and maximize hair regrowth.

The user is using oral Minoxidil, oral Dutasteride, microneedling, and RU58841 for hair loss, noticing slow progress with small hairs appearing. They are inconsistent with microneedling frequency, sometimes doing it weekly or skipping weeks.

The post and conversation are about a user's progress in treating hair loss using oral finasteride and topical minoxidil. The user expresses regret for not starting treatment earlier.

The post discusses the use of latanoprost foam for hair growth, with the user expressing concerns about its efficiency and safety. The user is currently using topical dutasteride, which maintains their hair but doesn't promote regrowth, and is seeking a product that doesn't affect hormone levels.

PP405 is discussed as a potential adjunct therapy for hair loss, with skepticism about its effectiveness and trial results. Users mention combining it with finasteride and minoxidil for better results, while others debate the root causes of hair loss and the limitations of current treatments.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Verteporfin considered for treating donor areas after hair transplants.

A medical student experienced hair loss slowing with Finasteride but developed severe, treatment-resistant insomnia. They tried various medications with little effect, suspecting Post-Finasteride Syndrome, and others suggested the insomnia might be linked to Finasteride's impact on neurosteroids.

A breakthrough in hair follicle cultivation using induced pluripotent stem cells (iPSCs) has been achieved, producing large hair follicles suitable for transplantation. Clinical trials for this hair multiplication technology are planned in partnership with Yinguan Biotechnology.

A user discussed their doctor lowering their Minoxidil dose from 5mg to 2.5mg, expressing concerns about losing hair gains. Other users suggested that 2.5mg is safer long-term and speculated the doctor is being cautious about side effects.

A 17-year-old male experiencing significant hair loss is using a prescribed topical treatment containing Minoxidil, Tretinoin, Dutasteride, and Latanoprost. He expresses concerns about the potential side effects of Dutasteride and oral Finasteride, and seeks advice on whether to continue with the treatment or consider alternatives.

The conversation is about a user considering joining a clinical study for Clascoterone (Breezula) after experiencing no results with topical finasteride and minoxidil, and side effects from oral finasteride. The user is seeking advice on clinical study participation and experiences.

Setipiprant trial for hair loss failed, showing no difference between placebo and treatment. Discussion also noted placebo users reporting side effects.

A dermatologist recommended switching from finasteride to dutasteride due to concerns about finasteride's side effects, despite the user not experiencing any. The user is considering transitioning strategies, including stopping finasteride immediately or overlapping both medications.

Verteporfin is being explored for its potential to improve hair transplant outcomes by reducing scarring and increasing donor hair follicles. There is skepticism about the results, with some claiming misleading presentation of evidence.